QuidelOrtho (QDEL) is expanding its QUICKVUE portfolio with the QUICKVUE Influenza + SARS Test, a CLIA-waived, 510(k)-cleared rapid, easy-to-use immunoassay designed for professional use in physician ...
QuidelOrtho Corporation recently expanded its QUICKVUE portfolio with the launch of the QUICKVUE Influenza + SARS Test, a rapid, CLIA-waived immunoassay for professional use that delivers simultaneous ...
SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a leading provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, ...
Says can add 2009 H1N1 influenza A virus reactivity info Shares rise 6 percent in pre-market trade Sept 17 (Reuters) - Quidel Corp , a provider of rapid diagnostic tests, said it received special ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback